Chloroquine sensitizes MDA-MB-231 cells to osimertinib through autophagy–apoptosis crosstalk pathway

References

• PodoF, BuydensLMC, DeganiH, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4(3):209–229. doi:10.1016/j.molonc.2010.04.00620537966
   PubMed Web of Science ®Google Scholar
• SiegelR, MaJ, ZouZ, JemalA. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.2120824399786
   PubMed Web of Science ®Google Scholar
• BenderRJ, Mac GabhannF. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One. 2013;8(5):e61788. doi:10.1371/journal.pone.006178823667446
   PubMed Web of Science ®Google Scholar
• PerouCM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16(Suppl 1):61–70. doi:10.1634/theoncologist.2011-S1-61
   PubMed Web of Science ®Google Scholar
• FleisherB, ClarkeC, Ait-OudhiaS. Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press). 2016;8:183–197. doi:10.2147/BCTT.S11465927785100
   PubMed Web of Science ®Google Scholar
• MonteroJC, Esparís-OgandoA, Re-LouhauMF, et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014;33(2):148–156. doi:10.1038/onc.2012.57223246963
   PubMed Web of Science ®Google Scholar
• ParkHS, JangMH, KimEJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27(9):1212–1222. doi:10.1038/modpathol.2013.25124406864
   PubMed Web of Science ®Google Scholar
• TanDS, MarchióC, JonesRL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111(1):27–44. doi:10.1007/s10549-007-9756-817922188
   PubMed Web of Science ®Google Scholar
• NielsenTO, StegnerAL, Wagner-MannC, Du BoisGC, AlexanderS, SauterER. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10. doi:10.1158/1078-0432.CCR-04-1002
   Web of Science ®Google Scholar
• Nogi H, Kobayashi T, Suzuki M, et al.EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncology Reports. 2009;21(2):413-417.
   Google Scholar
• CheangMC, VoducD, BajdikC, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–1376. doi:10.1158/1078-0432.CCR-07-165818316557
   PubMed Web of Science ®Google Scholar
• NakaiK, HungMC, YamaguchiH. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609–1623.27648353
   PubMed Web of Science ®Google Scholar
• TanX, ThapaN, SunY, AndersonRA. A kinase-independent role for EGF receptor in autophagy initiation. Cell. 2015;160(1–2):145–160. doi:10.1016/j.cell.2014.12.00625594178
   PubMed Web of Science ®Google Scholar
• LiuZ, HeK, MaQ, et al. Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer. PLoS One. 2017;12(5):e0177694. doi:10.1371/journal.pone.017769428531218
   PubMed Web of Science ®Google Scholar
• FungC, ChenX, GrandisJR, DuvvuriU. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol Ther. 2012;13(14):1417–1424. doi:10.4161/cbt.2200222954701
   PubMed Web of Science ®Google Scholar
• JuttenB, RouschopKM. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle. 2014;13(1):42–51. doi:10.4161/cc.2751824335351
   PubMed Web of Science ®Google Scholar
• MaiuriMC, ZalckvarE, KimchiA, KroemerG. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007;8(9):741–752. doi:10.1038/nrm223917717517
   PubMed Web of Science ®Google Scholar
• KimuraT, TakabatakeY, TakahashiA, IsakaY. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013;73(1):3–7. doi:10.1158/0008-5472.CAN-12-246423288916
   PubMed Web of Science ®Google Scholar
• KlionskyD.J., AbdelmohsenK AbeA. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1–222.26799652
   PubMed Web of Science ®Google Scholar
• TangZ-H, CaoW-X, SuM-X, ChenX, Lu-J-J. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2017;321:18–26. doi:10.1016/j.taap.2017.02.01728237877
   PubMed Web of Science ®Google Scholar
• WirawanE, Vande WalleL, KersseK, et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis. 2010;1(1):e18. doi:10.1038/cddis.2009.1621364619
   PubMed Web of Science ®Google Scholar
• WeiY, PattingreS, SinhaS, BassikM, LevineB. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008;30(6):678–688. doi:10.1016/j.molcel.2008.06.00118570871
   PubMed Web of Science ®Google Scholar
• SuZ, SkahS, UglandH, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015;14:48. doi:10.1186/s12943-014-0278-925743109
   PubMed Web of Science ®Google Scholar
• NikoletopoulouV, MarkakiM, PalikarasK, TavernarakisN. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 2013;1833(12):3448–3459. doi:10.1016/j.bbamcr.2013.06.00123770045
   PubMed Web of Science ®Google Scholar
• WangX, ChaoL, LiX, et al. Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and “triple-negative” breast cancers. Hum Pathol. 2010;41(3):401–406. doi:10.1016/j.humpath.2009.08.01819913278
   PubMed Web of Science ®Google Scholar
• HainesE, SchliengerS, ClaingA. The small GTPase ADP-ribosylation factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Cancer Biol Ther. 2015;16(10):1535–1547. doi:10.1080/15384047.2015.107173726176330
   PubMed Web of Science ®Google Scholar
• Espinoza-SanchezNA, VadilloE, BalandránJC, Monroy-GarcíaA, PelayoR, Fuentes-PananáEM. Evidence of lateral transmission of aggressive features between different types of breast cancer cells. Int J Oncol. 2017;51(5):1482–1496. doi:10.3892/ijo.2017.412829048610
   PubMed Web of Science ®Google Scholar
• ZhangN, FuJ-N, ChouT-C. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am J Cancer Res. 2016;6(1):97–104.27073727
   PubMed Web of Science ®Google Scholar
• ChouTC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-194720068163
   PubMed Web of Science ®Google Scholar
• YangYP, HuL-F, ZhengH-F, et al. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin. 2013;34(5):625–635. doi:10.1038/aps.2013.523524572
   PubMed Web of Science ®Google Scholar
• TaitSW, GreenDR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–632. doi:10.1038/nrm295220683470
   PubMed Web of Science ®Google Scholar
• FleisherB, UnumJ, ShaoJ, AnG. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. J Pharm Sci. 2015;104(1):266–275. doi:10.1002/jps.2428925418056
   PubMed Web of Science ®Google Scholar
• Tagrisso Granted Breakthrough Therapy Designation by US FDA for the 1st-Line Treatment of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. 2017; Available from: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-09102017.html. Accessed November 11, 2018.
   Google Scholar
• SoriaJC, OheY, VansteenkisteJ, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa171313729151359
   PubMed Web of Science ®Google Scholar
• VoraHH, PatelNA, ThakorePM, ShuklaSN. Immunohistochemical localization of wild-type EGFR, E746-A750 frame deletion in exon 19, and L858R point mutation in exon 21 in triple-negative breast cancer. Appl Immunohistochem Mol Morphol. 2015;23(9):653–660. doi:10.1097/PAI.000000000000012725789532
   PubMedGoogle Scholar
• CrossDA, AshtonSE, GhiorghiuS, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061. doi:10.1158/2159-8290.CD-14-033724893891
   PubMed Web of Science ®Google Scholar
• WendtMK, WilliamsWK, PascuzziPE, et al. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia. 2015;17(1):124–133. doi:10.1016/j.neo.2014.11.00925622905
   PubMed Web of Science ®Google Scholar
• LehmannBD, BauerJA, ChenX, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI4501421633166
   PubMed Web of Science ®Google Scholar
• DragowskaWH, WepplerSA, WangJC, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One. 2013;8(10):e76503. doi:10.1371/journal.pone.007650324146879
   PubMed Web of Science ®Google Scholar
• TanidaI, Minematsu-IkeguchiN, UenoT, KominamiE. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 2005;1(2):84–91. doi:10.4161/auto.1.2.169716874052
   PubMed Web of Science ®Google Scholar
• ThomasS, SharmaN, GoldenEB, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett. 2012;325(1):63–71. doi:10.1016/j.canlet.2012.05.03022664238
   PubMed Web of Science ®Google Scholar
• CostaRLB, HanHS, GradisharWJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018. doi:10.1007/s10549-018-4697-y
   Web of Science ®Google Scholar
• Blanco-AparicioC, RennerO, LealJFM, CarneroA. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28(7):1379–1386. doi:10.1093/carcin/bgm05217341655
   PubMed Web of Science ®Google Scholar
• ClarkAS, RobersonMS, LamkinTJ, VarvayanisS, YenA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1(9):707.12479367
   PubMed Web of Science ®Google Scholar
• YiYW, HongW, KangHJ, et al. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med. 2013;17(5):648–656. doi:10.1111/jcmm.1204623601074
   PubMed Web of Science ®Google Scholar
• YouKS, YiYW, KwakS-J, SeongY-S. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells. Int J Oncol. 2018;52(3):828–840. doi:10.3892/ijo.2018.424429344641
   PubMed Web of Science ®Google Scholar
• BuiNL, PandeyV, ZhuT, MaL, LobiePE. Bad phosphorylation as a target of inhibition in oncology. Cancer Lett. 2018;415:177–186. doi:10.1016/j.canlet.2017.11.01729175460
   PubMed Web of Science ®Google Scholar
• Djavaheri-MergnyM, MaiuriMC, KroemerG. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010;29(12):1717–1719. doi:10.1038/onc.2009.51920101204
   PubMed Web of Science ®Google Scholar
• RuvoloPP, DengX, MayWS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia. 2001;15(4):515–522.11368354
   PubMed Web of Science ®Google Scholar
• HuangP, XuX, WangL, ZhuB, WangX, XiaJ. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med. 2014;18(2):218–230. doi:10.1111/jcmm.1215324268047
   PubMed Web of Science ®Google Scholar
• ZhaoL, YangG, ShiY, SuC, ChangJ. Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. J Nanobiotechnology. 2015;13(1):57. doi:10.1186/s12951-015-0121-526395758
   PubMed Web of Science ®Google Scholar
• EspinaV, WysolmerskiJ, EdmistonK, LiottaLA. Attacking breast cancer at the preinvasion stage by targeting autophagy. Womens Health (Lond). 2013;9(2):157–170. doi:10.2217/whe.13.523477322
   PubMedGoogle Scholar